Objectives: Non-alcoholic fatty liver disease (NAFLD), recently reclassified as metabolic dysfunction-associated fatty liver disease (MAFLD), can also manifest in patients classified as non-MAFLD who do not meet MAFLD criteria. The involvement of cortisol and thyroid hormones may play a role in the pathogenesis of FLD by modifying the metabolism of specific lipoproteins, particularly apolipoprotein M ( Apo M ). This study investigated cortisol and thyroid hormones levels and Apo M gene expression in white blood cells (WBCs) of individuals with MAFLD, non-MAFLD, and healthy controls. Methods: The serum and WBCs of the study subjects were collected from patients with FLD (n=99) including 58 MAFLD and 41 non-MAFLD and healthy individuals (n=23). To investigate the gene expression of Apo M and thyroid and cortisol hormones, qRT-PCR and ELISA methods were used, respectively. Results: The Apo M gene expression was significantly lower in FLD patients, both non-MAFLD, and MAFLD patients compared to the control group (p<0.05). Total T4 and TSH hormone levels in the MAFLD patients were significantly decreased and increased compared to the control group, respectively (p<0.05). The cortisol level was significantly elevated in the FLD and MAFLD patients compared to the control group (p<0.01). Conclusions: Alterations in Apo M gene expression also cortisol and thyroid hormones levels in non-MAFLD patients were milder than MAFLD patients when compared to the control. Also, likely Apo M may be involved in FLD pathogenesis.
Killer immunoglobulin-like receptors (KIRs) and human leukocyte antigen (HLA) molecules play an essential role in regulating immune responses against hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. HLA-KIRs interactions are crucial for activating and inhibiting the natural killer (NK) cell system through a modulation that shapes these cells to kill infected cells and release cytokines. Regulation underlies the anti-viral function of the NK cell and profoundly affects viral clearance, immune evasion, and the course of disease. Activating KIRs such as KIR2DS1 and KIR3DS1 cooperate with specific HLA ligands in boosting NK cell responses against the virus, thereby facilitating viral elimination. In contrast, inhibitory KIRs like KIR2DL1 and KIR3DL1 bind to HLA-C2 and HLA-Bw4, respectively, imposing a dampening influence on NK cell activation, which allows the virus to persist and progress to chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). These variations in KIRs and HLA genes will also affect an individual’s susceptibility to infections, disease severity, and their response to antiviral therapies. Observation of the role of KIRs and their interaction with HLA at the immunogenetic level provides valuable insight into host-virus dynamics and opens up many therapeutic avenues. Targeting immunotherapies toward NK cell pathways and developing personalized medicine may boost antiviral immune responses and improve treatment outcomes in chronic viral hepatitis patients. This review recognizes HLA-KIRs interactions as potent biomarkers for disease progression and determining treatment strategies.
31 October 2025 in Avicenna Journal of Medical Biochemistry
Background: Fatty liver disease (FLD) is classified into metabolic dysfunction-associated fatty liver disease (MAFLD) and non-MAFLD based on the presence of metabolic abnormalities. The pathophysiology of FLD is complex; however, oxidative stress (OS) seems to play a significant role in its progression. Objectives: This study examined oxidative stress markers linked to FLD. Methods: A total of 64 patients with FLD, including 38 MAFLD and 26 non-MAFLD patients, respectively, were evaluated and compared with 22 healthy individuals. To assess oxidative stress, in addition to the activities of catalase (CAT), glutathione peroxidase (GPx), and superoxide dismutase (SOD) enzymes, total oxidant status (TOS), malondialdehyde (MDA), and total antioxidant capacity (TAC) were measured in the serum of the participants. Results: It was found that TOS, MDA, and TAC levels in the serum were significantly higher in the FLD group compared to the healthy individuals. Notably, these increases were more pronounced in the MAFLD group compared to the non-MAFLD group. Additionally, CAT and GPx enzyme activities were significantly elevated in patients with FLD than in the control group. The MAFLD group exhibited the highest CAT enzyme activity, while the non-MAFLD group demonstrated the highest GPx enzyme activity. Conversely, serum SOD enzyme activity was decreased across all studied groups, with no significant differences observed between them. Conclusion: Patients with MAFLD and non-MAFLD exhibit an imbalance in their oxidative stress systems. It appears that CAT and GPx enzymes probably play crucial roles in the antioxidant defense mechanisms in these patients, respectively.